Less Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome Combined With Noninvasive Ventilation in Anhui Province, China: A Retrospective Cohort Study

The less invasive surfactant application (LISA) technology has been widely used to manage breathing in premature infants. Premature infants with respiratory distress syndrome (RDS) were retrospectively analyzed and divided into 2 groups according to the drug delivery methods used: LISA versus tradit...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pediatrics 2023-10, Vol.62 (9), p.1109-1117
Main Authors: Zhang, Xue, Pan, Jiahua, Zhu, Liangmei, Ye, Yulan, Fan, Zhigang, Chen, Xin, Wang, Hui, Wei, Guangyou, Zhang, Lan
Format: Article
Language:English
Subjects:
Cohort analysis
Drug delivery
Dysplasia
Heart rate
Infants
Neonates
Newborn babies
Pediatrics
Premature babies
Premature birth
Respiratory distress syndrome
Surfactants
Ventilators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The less invasive surfactant application (LISA) technology has been widely used to manage breathing in premature infants. Premature infants with respiratory distress syndrome (RDS) were retrospectively analyzed and divided into 2 groups according to the drug delivery methods used: LISA versus traditional pulmonary surfactant injection (INSURE). The decrease of transcutaneous saturation (TcSO2) and heart rate during surfactant delivery in the LISA group was higher than that in the INSURE group (P < .05). Between the 2 groups, there was no significant difference in the change in partial pressure of oxygen/fraction of inspired oxygen value before and after drug delivery; second-use pulmonary surfactant; noninvasive ventilation (NIV) failure rate; incidence of some complications; duration of NIV use; hospitalization time; and mortality (P > .05). However, the incidence of bronchopulmonary dysplasia (BPD) in the LISA group was lower than that in the INSURE group (P < .05). The clinical efficacy of LISA combined with the NIV treatment in premature infants with RDS was clear, and this treatment could reduce the incidence of BPD.
ISSN:0009-9228
1938-2707
DOI:10.1177/00099228231152859